Jefferies Assumes Taysha Gene Therapies (TSHA) at Buy, Raises PT to $45

May 11, 2021 7:56 AM

Jefferies analyst Eun Yang assumes coverage on Taysha Gene Therapies (NASDAQ: TSHA) with a Buy rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found